Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJul 03, 2026
DataAggregated Company Financials
Companies66
  • 7D3.2%
  • 3M15.3%
  • 1Y16.7%
  • YTD-4.6%

In the last week, the Life Sciences industry is up 5.0%, with Thermo Fisher Scientific up 4.3%. During this same period, the Nautilus Biotechnology underperformed, falling 22%. In the last 12 months, the industry was up 15%. Earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 03 Jul 2026US$641.4bUS$151.2bUS$13.6b45.2x47x4.2x
Sun, 31 May 2026US$595.4bUS$150.6bUS$13.8b37.9x43.3x4x
Tue, 28 Apr 2026US$546.1bUS$149.1bUS$14.4b30.9x38x3.7x
Thu, 26 Mar 2026US$553.6bUS$147.8bUS$14.0b36x39.4x3.7x
Sat, 21 Feb 2026US$597.1bUS$147.7bUS$13.8b33.8x43.2x4x
Mon, 19 Jan 2026US$693.3bUS$145.8bUS$12.4b36.8x56.1x4.8x
Wed, 17 Dec 2025US$660.5bUS$145.8bUS$12.5b34.7x52.9x4.5x
Fri, 14 Nov 2025US$657.5bUS$145.7bUS$12.2b34.8x54.1x4.5x
Sun, 12 Oct 2025US$609.0bUS$144.3bUS$14.6b31.7x41.8x4.2x
Tue, 09 Sep 2025US$582.1bUS$144.3bUS$14.6b29.8x40x4x
Thu, 07 Aug 2025US$555.5bUS$144.1bUS$13.0b28.2x42.7x3.9x
Sat, 05 Jul 2025US$548.4bUS$142.9bUS$9.1b36.4x60.1x3.8x
Mon, 02 Jun 2025US$504.6bUS$142.9bUS$9.2b32.4x54.6x3.5x
Wed, 30 Apr 2025US$518.0bUS$142.5bUS$10.0b37.8x51.8x3.6x
Fri, 28 Mar 2025US$589.1bUS$143.0bUS$9.9b38.5x59.5x4.1x
Sun, 23 Feb 2025US$619.6bUS$143.3bUS$9.7b38.8x63.8x4.3x
Tue, 21 Jan 2025US$681.4bUS$142.4bUS$10.2b43.8x66.8x4.8x
Thu, 19 Dec 2024US$664.1bUS$142.4bUS$10.2b43.3x65x4.7x
Sat, 16 Nov 2024US$667.9bUS$142.4bUS$10.4b41.8x64.4x4.7x
Mon, 14 Oct 2024US$731.7bUS$141.8bUS$8.5b37.7x86.1x5.2x
Wed, 11 Sep 2024US$739.9bUS$141.8bUS$8.5b38.3x87.1x5.2x
Fri, 09 Aug 2024US$714.4bUS$141.6bUS$8.4b38.7x84.7x5x
Sun, 07 Jul 2024US$664.6bUS$141.3bUS$12.2b38.8x54.6x4.7x
Tue, 04 Jun 2024US$702.1bUS$141.3bUS$12.4b38.5x56.5x5x
Thu, 02 May 2024US$706.3bUS$141.5bUS$12.7b39.4x55.8x5x
Sat, 30 Mar 2024US$744.3bUS$142.1bUS$12.8b44x58.1x5.2x
Mon, 26 Feb 2024US$729.9bUS$142.1bUS$12.4b43.7x58.9x5.1x
Wed, 24 Jan 2024US$697.0bUS$153.8bUS$14.2b35.8x49.2x4.5x
Fri, 22 Dec 2023US$687.0bUS$153.8bUS$14.2b37.5x48.2x4.5x
Sun, 19 Nov 2023US$614.3bUS$153.9bUS$13.9b33.5x44.2x4x
Tue, 17 Oct 2023US$632.5bUS$154.6bUS$11.2b33.2x56.5x4.1x
Thu, 14 Sep 2023US$692.7bUS$154.6bUS$11.2b33.1x61.8x4.5x
Sat, 12 Aug 2023US$725.3bUS$154.7bUS$11.5b32x63.1x4.7x
Mon, 10 Jul 2023US$685.3bUS$152.4bUS$12.5b29.6x54.8x4.5x
Price to Earnings Ratio

54.8x


Total Market Cap: US$685.3bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.1x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 46.0x which is lower than its 3-year average PE of 56.1x.
  • The industry is trading close to its 3-year average PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 2.9% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.38%
Healthcare4.96%
Life Sciences3.17%
Clinical Research and Equipment3.17%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$523.443.5%
+US$6.6b		21.9%PE28.4x
IQV IQVIA HoldingsUS$207.0411.1%
+US$3.4b		26.1%PE24.9x
DHR DanaherUS$197.932.4%
+US$3.3b		-2.6%PE38.1x
ILMN IlluminaUS$188.686.9%
+US$1.8b		87.2%PE33.5x
WST West Pharmaceutical ServicesUS$365.745.5%
+US$1.4b		64.6%PE47.6x

Latest News

WST
US$365.74
West Pharmaceutical Services
7D
5.5%
1Y
64.6%
TMO
US$523.44
Thermo Fisher Scientific
7D
3.5%
1Y
21.9%
A
US$130.69
Agilent Technologies
7D
-3.6%
1Y
7.7%
TEM
US$60.27
Tempus AI
7D
9.8%
1Y
-1.1%
TECH
US$70.83
Bio-Techne
7D
0.2%
1Y
33.3%
Narrative Update • Jul 01

TECH: Pending Merger Premium Will Constrain Future Earnings Appeal

Bio-Techne's updated analyst price target has been trimmed from about $56.78 to $55.05, as analysts factor in slightly higher assumed revenue growth and P/E levels, along with modestly lower profit margin estimates. What’s in the News for Bio-Techne Merck KGaA agreed to acquire Bio-Techne in an all cash transaction valued between US$11.3b and US$11.5b, which Merck states represents about a 36% premium to Bio-Techne’s trading price at announcement.
DHR
US$197.93
Danaher
7D
2.4%
1Y
-2.6%
MTD
US$1,308.43
Mettler-Toledo International
7D
5.2%
1Y
8.2%
IQV
US$207.04
IQVIA Holdings
7D
11.1%
1Y
26.1%
MEDP
US$556.70
Medpace Holdings
7D
7.1%
1Y
73.2%
Narrative Update • Jun 29

MEDP: Slower Revenue Outlook And Lower P/E Assumptions Will Pressure Expectations

Analysts have trimmed their price targets on Medpace Holdings, with the updated fair value estimate moving from $500.08 to $443.50 as they factor in slightly higher discount rates, more moderate revenue growth assumptions, a marginally lower profit margin outlook, and a modestly reduced future P/E multiple. Analyst Commentary Recent research updates on Medpace Holdings point to a more cautious stance on valuation, with several firms trimming their price targets even as they recognize the company’s execution strengths and long-term opportunities.
RGEN
US$142.40
Repligen
7D
-1.9%
1Y
11.7%
CYRX
US$15.50
Cryoport
7D
-2.4%
1Y
102.3%
ILMN
US$188.66
Illumina
7D
6.2%
1Y
87.2%
Narrative Update • Jun 29

ILMN: Clinical Execution And Sector Funding Support A Cautiously Balanced Outlook

The analyst fair value estimate for Illumina has been lifted by $10 to $185, reflecting higher Street price targets and analyst expectations for stronger customer spending and margins, supported by recent research, survey feedback, and sector funding trends. Analyst Commentary Recent Street research around Illumina points to a more constructive tone, with several bullish analysts highlighting improving customer sentiment, sector funding trends, and clearer execution on the clinical side.
FTRE
US$17.26
Fortrea Holdings
7D
-2.5%
1Y
230.7%
BIO
US$296.86
Bio-Rad Laboratories
7D
-0.5%
1Y
18.0%
Narrative Update • Jun 18

BIO: Activist Campaign And Ongoing Buybacks Will Drive Future Share Price

Analysts have kept their $320 price target on Bio-Rad Laboratories steady, citing only modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions that offset each other in their valuation models. What’s in the News for Bio-Rad Laboratories On May 18, 2026, Elliott Investment Management LP disclosed a significant stake in Bio-Rad Laboratories and called for actions aimed at raising the share price, citing what it describes as more than a 70% decline from a peak in late 2021.
ALMR
US$25.94
Alamar Biosciences
7D
-3.5%
1Y
n/a
NAUT
US$1.73
Nautilus Biotechnology
7D
-23.8%
1Y
111.0%